For the year ending 2025-12-31, BFRIW had $487K increase in cash & cash equivalents over the period. -$13,363K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -10,536 |
| Loss on debt extinguishment | 0 |
| Other receivables, related party | 0 |
| Depreciation and amortization | 138 |
| Stock-based compensation | 951 |
| Non-cash interest expense | 491 |
| Allowance for credit losses | -69 |
| Gain on sale of asset held for sale | 700 |
| Loss from termination of operating leases | -19 |
| Realized/unrealized loss in investment, related party | 2 |
| Accounts receivable | 1,907 |
| Prepaid expenses and other assets | 1,728 |
| Other assets, related party | 686 |
| Inventories | -1,445 |
| Accounts payable | -2 |
| Accounts payable, related parties, net | -533 |
| Operating lease liabilities | -683 |
| Accrued expenses and other liabilities | 610 |
| Change in fair value of warrant liabilities | -899 |
| Reduction in the carrying amount of right-of-use assets | 730 |
| Cash flows used in operating activities | -13,361 |
| Sales of investment, related party | 0 |
| Purchase of intangible assets | 0 |
| Proceeds from sale of asset held for sale | 3,000 |
| Purchases of property and equipment | 2 |
| Cash flows provided by (used in) investing activities | 2,998 |
| Proceeds from issuance of series b-1 preferred stock and warrants to purchase series b-3 preferred stock, net of issuance costs | 0 |
| Proceeds from issuance of series b-3 preferred stock from exercise of warrants | 0 |
| Payment of principal short-term debt | 0 |
| Proceeds from issuance of series c preferred stock, net of offering costs | 10,850 |
| Cash flows provided by financing activities | 10,850 |
| Net increase in cash and cash equivalents | 487 |
| Net increase in cash and cash equivalents | 487 |
| Cash, cash equivalents and restricted cash, at the beginning of the year | 6,105 |
| Cash, cash equivalents and restricted cash, at the end of the year | 6,592 |
Biofrontera Inc. (BFRIW)
Biofrontera Inc. (BFRIW)